Cencora raises FY2025 adjusted EPS guidance range by $0.05 to $15.30-$15.60

Cencora, Inc.

Guidance increase driven by continued momentum in U.S. Healthcare Solutions segment during Q2 2025.
No change to expectations for recently completed Retina Consultants of America acquisition.
Adjusted diluted EPS excludes acquisition intangibles, LIFO, litigation, and other items.
Company presented updated guidance at Leerink Partners Global Healthcare Conference on March 10, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.